Innate Pharma S.A. (IPHA) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed picture. While there is a positive revenue increase and reduced net loss, the absence of a shareholder return plan and increased operating expenses are concerns. The strategic initiatives and partnerships, especially with AstraZeneca, are promising but come with risks and uncertainties. The lack of clarity in management responses during the Q&A also adds to the uncertainty. Overall, the sentiment is neutral, with balanced positive and negative factors.
Key Financial Performance
Revenue Innate Pharma reported revenue of €15.2 million for Q1 2026, a 20% increase year-over-year, primarily driven by higher collaboration revenue from its partnerships with AstraZeneca.
Operating Expenses Operating expenses were €18.5 million, up 10% compared to Q1 2025, due to increased R&D investments in pipeline programs such as lacutamab and IPH4502.
Net Loss Net loss for the quarter was €3.3 million, an improvement from the €5.6 million net loss in Q1 2025, attributed to higher revenue and controlled operating expenses.
Cash Position The cash position stood at €102.4 million as of March 31, 2026, compared to €110.7 million at the end of December 2025, reflecting operational expenditures and investments in R&D.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Lacutamab: Updates were provided on the development progress of lacutamab.
IPH4502: Updates were provided on the development progress of IPH4502.
Next-generation ADCs: Updates were provided on the development progress of next-generation ADCs.
Monalizumab and IPH5201: Updates were provided on the AstraZeneca partner program, including monalizumab and IPH5201.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The presentation includes forward-looking statements that involve risks and uncertainties, which could cause actual results to differ materially from expectations.
Pipeline development: Challenges in advancing the development of lacutamab, IPH4502, and next-generation ADCs, as well as the AstraZeneca partner program, including monalizumab and IPH5201, could impact strategic objectives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Overview: Jonathan Dickinson will provide a strategic overview and outlook.
Lacutamab, IPH4502, and Next-Generation ADCs: Updates will be provided on lacutamab, IPH4502, and next-generation ADCs.
AstraZeneca Partner Program: Updates will be provided on the AstraZeneca partner program, including monalizumab and IPH5201.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ADCs AstraZeneca
AstraZeneca partner
BTIG LLC
CEO Dickinson
CEO Director
CFO QA
COO Daina
Commercial Dickinson
Communication Commercial
Communications Commercial
Daina Graybosch
Dickinson CEO
Dickinson overview
Director Executive
Division Jeet
Division Ladies
Division Liu
Division Swayampakula
EDT Executive
Executive VP
IPH closing
IPH generation
Innate Pharma
Jeet Mukherjee
LLC Research
Liu Lucid
Mukherjee BTIG
Officer Chief
Officer EDT
Pharma Update
QA Dickinson
Relations Communication
Research Division
VP COO
outlook Chief
partner program
remark CFO
IPHA Transcript
Innate Pharma S.A. (IPHA) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call summary presents a mixed picture. While there is a positive revenue increase and reduced net loss, the absence of a shareholder return plan and increased operating expenses are concerns. The strategic initiatives and partnerships, especially with AstraZeneca, are promising but come with risks and uncertainties. The lack of clarity in management responses during the Q&A also adds to the uncertainty. Overall, the sentiment is neutral, with balanced positive and negative factors.
Innate Pharma S.A. (IPHA) Q4 2025 Earnings Call Transcript
Unknown3-26
The earnings call presents a mixed picture. While there are positive developments in clinical trials and partnerships, there are risks associated with trial outcomes and partnership dependencies. Financials show reduced R&D expenses, but operating expenses remain high, and cash position is stable. The Q&A reveals interest in IPH4502 and MATISSE programs, but management's lack of clarity on certain details introduces uncertainty. Overall, the sentiment is balanced by positive clinical progress and financial stability, offset by risks and unclear guidance, suggesting a neutral stock price reaction in the short term.
Innate Pharma S.A. (IPHA) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call presents a mixed outlook: strong financial metrics with a cash runway through Q3 2026, positive trial progress, and potential for accelerated approval of Lacutamab. However, uncertainties remain due to potential supply chain issues in ADCs, lack of clear guidance on partnerships, and management's vague responses on future plans. The neutral sentiment reflects balanced positive and negative factors, with no strong catalysts to move the stock significantly.
Innate Pharma S.A. (IPHA) Q2 2025 Earnings Call Transcript
Unknown9-17
The earnings call highlighted several concerns: financial constraints with a limited cash runway, significant operating expenses, and dependency on a few key programs. While there were collaborations with major companies, the lack of diversification and potential regulatory hurdles for key drugs add risks. The Q&A revealed uncertainties about strategic refocus and financial impacts, with management avoiding specific answers, raising investor concerns. Overall, the company's challenges and lack of clear positive catalysts suggest a negative stock price movement.
IPHA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
